He has been working as a Physician Specialist in Urology at University Hospital La Moraleja in Madrid since May 2015 and as a Physician Specialist in Urology and Infertility at OVOCLINIC in Madrid since September 2021. Previously, he was a resident at the Urology Department of University Hospital Ramón y Cajal in Madrid, Spain, from May 2010 to May 2015, and worked as a General Physician at Company Medycsa, Calle Valentín Beato 5, Madrid, between 2009 and 2010. He completed a Fellowship in Laparoscopic and Robotic Urological Surgery at Saint Augustin Clinic, Bordeaux (France) from September to November 2014 and participated in the Salzburg ESU Weill Cornell Seminar in Masterclass in Urology, organised by the European Association of Urology, European School of Urology (ESU), and Weill Cornell Medicine, earning 37 DFP credits from the Austrian Chamber of Physicians in Salzburg, Austria, from 9th to 15th July 2017. From 2010 to 2014, he was a Professor of Urology at CTO Medicina, delivering 180 hours of lectures under the direction of Dr. Roberto Garcia Leal. He supervised residents during their incorporation into the Department of Urology and provided education and oversight to students of the Medicine Degree at Universidad Francisco de Vitoria as well as to residents of Gynecology.

From 2020 to 9th June 2023, he was a Ph.D. student in Medicine and Surgery at Universidad Autónoma de Madrid, where he studied the diagnostic validity of predictive models in prostate cancer using the Prostate Imaging and Data Reporting System version 2 (PIRADSv2) and PSA density. Since 2023, he has been the principal investigator of a randomised, double-blind, placebo-controlled study evaluating the effect of a probiotic on urinary tract microbiota in women with recurrent urinary tract infections (rUTI), study code IC-HULM-007-23, known as the PROBUTI study. Since 2021, he has been an independent technical evaluator of research projects, R+D+I, and technological innovation. He is currently the principal investigator in the Prostate Imaging using MRI +/- contrast Enhancement (PRIME) study at University College London (UCL), which assesses whether bi-parametric MRI is non-inferior to multi-parametric MRI in diagnosing clinically significant prostate cancer. Additionally, he actively collaborates as the principal investigator in the phase 3 clinical trial E.mbrace Amendment 2 VAC52416 (JNJ-78901563 [ExPEC9V]), a study aimed at assessing the efficacy, safety, and immunogenicity of vaccination with ExPEC9V in preventing invasive extraintestinal pathogenic Escherichia coli disease in adults aged 60 years and older with a history of urinary tract infection in the past two years.

His ongoing research projects include a comparative study between multiparametric magnetic resonance systems of 1.5 and 3 Teslas using the PIRADS version 2 classification in the diagnosis of prostate cancer (registered under number 40/2021); a cross-sectional study of PSA density assessment and multiparametric resonance as predictors of prostate cancer (registered under number 39/2021); and the evaluation of the Oncotype Dx genetic test in therapeutic decisions for low-risk prostate cancer, a multicenter study (registered under number 29/2021). From 2020 to the present, he has been conducting research on predictive models and validation of diagnostic tests in prostate cancer, focusing on multiparametric prostate MRI and fusion prostate biopsy as part of his PhD at Universidad Autónoma de Madrid. Between 2018 and 2019, he actively collaborated in the RITUMAN study, a multicenter and coordinated study on the management of patients with recurrent urinary tract infections. From 2016 to 2017, he contributed to the PREVENT-LIT study, which focused on the management of patients with urolithiasis. From 2011 to 2013, he participated in the EMPARO-CU study, a multicenter and coordinated study examining the care process and outcomes in a cohort of patients diagnosed with urological cancer (bladder and prostate).